tradingkey.logo

NNNN

NNNN
View Detailed Chart

51.810USD

+6.560+14.50%
Close 07/09, 16:00ETQuotes delayed by 15 min
7.37BMarket Cap
--P/E TTM

NNNN

51.810

+6.560+14.50%
Intraday
1m
30m
1h
D
W
M
D

Today

+14.50%

5 Days

+43.12%

1 Month

+515.32%

6 Months

0.00%

Year to Date

0.00%

1 Year

0.00%

View Detailed Chart

Agency Rating

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Buy
Sell(1)
Neutral(0)
Buy(6)
Indicators
Sell(1)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
4.934
Buy
RSI(14)
94.491
Overbought
STOCH(KDJ)(9,3,3)
96.119
Overbought
ATR(14)
5.606
High Vlolatility
CCI(14)
155.348
Buy
Williams %R
1.865
Overbought
TRIX(12,20)
8.335
Sell
StochRSI(14)
100.000
Overbought
Moving Average
Sell(0)
Neutral(0)
Buy(4)
Indicators
Value
Direction
MA5
--
--
MA10
--
--
MA20
--
--
MA50
--
--
MA100
--
--
MA200
--
--

News

More news coming soon, stay tuned...

Company

Anbio Biotechnology is a Germany-based company. The Company is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products encompasses solutions for various applications, including over-the-counter (OTC) utilization, point-of-care (POCT) settings, and laboratory applications. The Company's product detects biomarkers associated with medical domains. These domains encompasses infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. In addition, the Company's IVD products are in line with multiple sample collection matrices, including serum, plasma, whole blood, feces, urine, and saliva, for both healthcare providers and patients. Its primary research and development activities for all IVD products includes Biomarker Discovery and Validation, Assay Development, Validation - Clinical and Analytical and Platform Transfer.
Ticker SymbolNNNN
CompanyAnbio Biotechnology
CEOMr. Michael Lau
Website
KeyAI